Medical Developments International (MVP) has announced that it will buy back the European Union rights to its Penthrox methoxyflurane inhaler from Mundipharma for €3 million, plus a 5% royalty up to a maximum of €5 million. The companies plan a 6-month transition period beginning September 1, 2020. Penthrox is approved throughout Europe for the emergency treatment … [Read more...] about Medical Developments International buys back European Union rights to Penthrox inhaler from Mundipharma
News
Verona initiates Phase 2b trial of ensifentrine MDI for COPD
Verona Pharma has announced the initiation of a Phase 2b trial of its ensifentrine MDI for the treatment of COPD in the UK, with results expected in the first half of 2021. In March 2020, Verona announced positive results from a Phase 2a trial of the MDI and noted that the second part of the trial would be delayed due to the COVID-19 pandemic. The Phase 2b trial … [Read more...] about Verona initiates Phase 2b trial of ensifentrine MDI for COPD
Lannett gets rights to distribute Respirent’s generic Flovent Diskus in the US
According to Lannett, the company has signed an agreement with Chinese inhaled drug developer Respirent for exclusive rights to distribute Respirent's generic version of GSK's Flovent Diskus fluticasone propionate DPI, which is in early development. In October 2019, Lannett announced a US distribution deal with Respivent for that company's generic version of GSK's … [Read more...] about Lannett gets rights to distribute Respirent’s generic Flovent Diskus in the US
United Therapeutics submits sNDA for use of Tyvaso in PH-ILD
The FDA has accepted a supplemental NDA for United Therapeutics's Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), the company said. In February 2020, United Therapeutics announced that the Phase 3 INCREASE study of Tyvaso in PH-ILD patients had met its primary endpoint. Tyvaso … [Read more...] about United Therapeutics submits sNDA for use of Tyvaso in PH-ILD
Union Therapeutics acquires option for TFF’s dry powder niclosamide
Danish pharma company Union Therapeutics has entered into an agreement with TFF Pharmaceuticals for an option to license TFF's dry powder niclosamide, the companies announced. The deal includes potential inhaled and oral formulations of niclosamide for the treatment of COVID-19 and is worth up to $210 million in milestone payments as well as royalties on any … [Read more...] about Union Therapeutics acquires option for TFF’s dry powder niclosamide
Proveris Scientific announces two appointments
Aerosol testing company Proveris Scientific has announced two new appointments: Joseph Werbeck rejoins the company as Senior Director of Technical Service and Mohamed Eldam joins Proveris as Applications Chemist. Werbeck, who will report to VP of Technical Service Alberto Correia, served as Director of Technical Service at Proveris from 2014-2018 before leaving for a … [Read more...] about Proveris Scientific announces two appointments
AstraZeneca increases production of FluMist Quadrivalent for 2020-2021 flu season
AstraZeneca has announced that the first doses of its FluMist Quadrivalent live intranasal flu vaccine for the 2020-2021 US influenza season have shipped. FluMist Quadrivalent is approved for use in children over the age of 2 and adults up to age 49. The company said that it has increased planned production of the vaccine by more than 25% in response to … [Read more...] about AstraZeneca increases production of FluMist Quadrivalent for 2020-2021 flu season
TFF Pharmaceuticals raises almost $26 million
TFF Pharmaceuticals announced that the company has raised $25.9 million in a private placement, with the funds to be used to "to accelerate the expansion of the company’s internal development portfolio beyond its programs for voriconazole and tacrolimus inhalation powders." Earlier this year, the company announced that it was working on a universal flu vaccine in … [Read more...] about TFF Pharmaceuticals raises almost $26 million
Royalty Pharma provides funding for Biohaven’s zavegepant development program
Biohaven Pharmaceutical will receive up to $250 million from Royalty Pharma on closing of a deal to fund development of its zavegepant (formerly vazegepant) calcitonin gene-related peptide (CGRP) receptor antagonist program, which includes intranasal zavegepant, the companies said. In March 2020, Biohaven announced that it was ready to advance intranasal … [Read more...] about Royalty Pharma provides funding for Biohaven’s zavegepant development program
Aerovate Therapeutics raises $72.6 million for development of imatinib DPI for PAH
An RA Capital Management company called Aerovate Therapeutics has raised $72.6 million in Series A financing for development of its AV-101 dry powder imatinib for the treatment of pulmonary arterial hypertension (PAH), the company said. A registrational study of AV-101 is expected to begin by mid-2021. According to the announcement, "The concept and proprietary … [Read more...] about Aerovate Therapeutics raises $72.6 million for development of imatinib DPI for PAH